Halozyme Therapeutics, Inc. (NASDAQ: HALO) today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program issued by the U.S. Centers for Medicare & Medicaid Services on November 5.
"Based on our analysis of CMS's final rule and the statutory framework established under the (so-called) One Big Beautiful Bill Act, Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
“Importantly, there is also no projected impact on the Company's ability to execute new ENHANZE® partnership agreements where improving the patient treatment experience and competitive differentiation continue to be the top reasons ENHANZE is utilized," commented CEO Helen Torley.
This outlook is supported by statements in the final rule affirming that orphan drug protections remain applicable and addressing the impacts of biosimilar entry on Program eligibility.
HALO shares fell $17.56, or 14.3%, to $105.40.
